Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
Robak, Tadeusz × Huang, Huiqiang Jin, Jie Zhu, Jun Liu, Ting Samoilova, Olga Pylypenko, Halyna Verhoef, Gregor Siritanaratkul, Noppadol Osmanov, Evgenii Alexeeva, Julia Pereira, Juliana Drach, Johannes Mayer, Jiri Hong, Xiaonan Okamoto, Rumiko Pei, Lixia Rooney, Brendan van de Velde, Helgi Cavalli, Franco LYM-3002 Investigators #
New England Journal of Medicine vol:372 issue:10 pages:944-53
The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma.